Quantum BioPharma shareholders approve all meeting items; insider share placement closes
Nasdaq-listed Quantum BioPharma won approval for a share consolidation of up to 10-for-1 and a name change, and closed a C$80.86 placement of voting shares.
Shareholders of Quantum BioPharma (NASDAQ: QNTM) backed every item at the company's annual and special meeting on 10 November 2026. They elected all five director nominees and re-appointed MNP LLP as auditor.
They also approved an omnibus equity plan, a share consolidation of up to 10-for-1 and a change of company name. The summary of the announcement does not give the new name or the timing of the consolidation.
The day before the meeting, on 9 November 2026, the company closed a non-brokered placement of 26 Class A multiple voting shares at C$3.11 each. Gross proceeds were C$80.86. The shares went to two holders linked to company insiders.
After the placement, the Class A multiple voting shares carry about 68.22% of the votes. The announcement as summarised does not mention any clinical, regulatory or product developments.
Why it matters
- The announcement contains no product, trial or regulatory information, so it has no direct bearing on regulatory, pharmacovigilance or quality workstreams.
- Teams that deal with Quantum BioPharma as a partner or sponsor may need to update company records once the name change takes effect, though no date was given.
- The new name and the consolidation ratio and timing are not specified in the available material and should be checked against the company's formal filings.
Company's press release (SEC filing): Quantum Biopharma Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativa
TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AML
CHMP backs Roche's Gazyvaro as add-on therapy for autoantibody-positive lupus
